CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03123783 |
|
Recruitment Status :
Completed
First Posted : April 21, 2017
Results First Posted : December 5, 2023
Last Update Posted : December 26, 2023
|
Sponsor:
Apexigen America, Inc.
Collaborator:
Bristol-Myers Squibb
Information provided by (Responsible Party):
Apexigen America, Inc.
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
This study is a Phase 1-2 open-label dose escalation study of the immuno-activating monoclonal antibody APX005M administered in combination with nivolumab to adult subjects with non-small cell lung cancer or metastatic melanoma. The Phase 1 portion is intended to establish the maximum tolerated dose and the recommended phase 2 dose of APX005M when administered in combination with nivolumab. The Phase 2 portion of the study will evaluate safety and efficacy of the combination.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Cancer Non Small Cell Lung Cancer Metastatic Metastatic Melanoma Neoplasm of Lung Melanoma | Drug: APX005M Drug: Nivolumab | Phase 1 Phase 2 |
APX005M-002 is an open-label Phase 1-2 study and comprises a dose-escalation portion (Phase 1) followed by a Phase 2 tumor specific portion.
Eligible subjects with non-small cell lung cancer or metastatic melanoma will receive intravenous APX005M in combination with nivolumab until disease progression, unacceptable toxicity or death, whichever occurs first.
Study objectives include:
- Determine the maximum tolerated dose and the recommended phase 2 dose of APX005M when given in combination with nivolumab
- Evaluate safety of the APX005M and nivolumab combination
- Evaluate the objective response rate, duration of response and median PFS by RECIST 1.1 in subjects with non-small cell lung cancer or metastatic melanoma receiving APX005M in combination with nivolumab
- Determine the PK of APX005M
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 140 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Sequential Assignment |
| Intervention Model Description: | Phase 1b dose escalation with up to 4 sequential dose levels. Followed by Phase 2 dose expansion at Recommended Phase 2 Dose in 3 parallel disease cohorts. |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination With Nivolumab in Subjects With Non-small Cell Lung Cancer and Subjects With Metastatic Melanoma |
| Actual Study Start Date : | July 10, 2017 |
| Actual Primary Completion Date : | November 16, 2020 |
| Actual Study Completion Date : | November 16, 2020 |
Resource links provided by the National Library of Medicine
MedlinePlus related topics:
Melanoma
Drug Information
available for:
Nivolumab
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Phase 1b escalation 0.03 mg/kg
Non-small cell lung cancer (NSCLC) or metastatic melanoma APX005M 0.03 mg/kg and nivolumab 360 mg every 3 weeks |
Drug: APX005M
APX005M is a CD40 agonistic monoclonal antibody Drug: Nivolumab Nivolumab is an immune checkpoint (PD-1) blocking antibody
Other Name: Opdivo |
|
Experimental: Phase 1b escalation 0.1 mg/kg
Non-small cell lung cancer (NSCLC) or metastatic melanoma APX005M 0.1 mg/kg and nivolumab 360 mg every 3 weeks |
Drug: APX005M
APX005M is a CD40 agonistic monoclonal antibody Drug: Nivolumab Nivolumab is an immune checkpoint (PD-1) blocking antibody
Other Name: Opdivo |
|
Experimental: Phase 1b escalation 0.3 mg/kg
Non-small cell lung cancer (NSCLC) or metastatic melanoma APX005M 0.3 mg/kg and nivolumab 360 mg every 3 weeks |
Drug: APX005M
APX005M is a CD40 agonistic monoclonal antibody Drug: Nivolumab Nivolumab is an immune checkpoint (PD-1) blocking antibody
Other Name: Opdivo |
|
Experimental: Phase 2 expansion Cohort 1
Immunotherapy naïve, metastatic or locally advanced NSCLC APX005M 0.3 mg/kg and nivolumab 360 mg every 3 weeks |
Drug: APX005M
APX005M is a CD40 agonistic monoclonal antibody Drug: Nivolumab Nivolumab is an immune checkpoint (PD-1) blocking antibody
Other Name: Opdivo |
|
Experimental: Phase 2 expansion Cohort 2
Metastatic melanoma progressing during treatment with anti-PD-1/PD-L1 therapy APX005M 0.3 mg/kg and nivolumab 360 mg every 3 weeks |
Drug: APX005M
APX005M is a CD40 agonistic monoclonal antibody Drug: Nivolumab Nivolumab is an immune checkpoint (PD-1) blocking antibody
Other Name: Opdivo |
|
Experimental: Phase 2 expansion Cohort 3
Metastatic or locally advanced NSCLC progressing during treatment with anti-PD-1/PD-L1:
|
Drug: APX005M
APX005M is a CD40 agonistic monoclonal antibody Drug: Nivolumab Nivolumab is an immune checkpoint (PD-1) blocking antibody
Other Name: Opdivo |
Primary Outcome Measures :
- Number of Participants Experiencing Dose-limiting Toxicities (DLTs) [ Time Frame: Up to 21 days following first dose of APX005M and nivolumab ]
All toxicities were graded according to the NCI-CTCAE version 4.03. DLT was defined as any of the following events attributed to APX005M and nivolumab combination:
- Grade 4 hematologic toxicity lasting ≥ 7 days (except asymptomatic lymphopenia)
- Grade 3 or 4 neutropenia with a single temperature of >38.3◦ C (101◦ F) or a sustained temperature of ≥38◦ C (100.4◦ F) for more than one hour
- Grade 4 thrombocytopenia or Grade ≥3 thrombocytopenia with signs or symptoms of bleeding or requiring platelet transfusion
- Grade 4 non-hematologic toxicity
- Grade 3 non-hematologic toxicity lasting >3 days despite optimal supportive care
- Any Grade ≥ 3 non-hematologic laboratory value if: medical intervention is required to treat the subject, abnormality leads to hospitalization, or abnormality persists for >1 week
- Failure to recover from a treatment-related AE to baseline or ≤ Grade 1 within 12 weeks of last dose of investigational product
- Grade 5 toxicity.
- Maximum Tolerated Dose (MTD) of APX005M + Nivolumab (Phase 1b) [ Time Frame: Up to 21 days following first dose of APX005M and nivolumab ]Establish the MTD dose of APX005M combined with 360 mg of nivolumab for which for which < 33% of DLT- evaluable participants experience a DLT. In Phase 1b, the RP2D was based on the overall safety and tolerability of the combination of APX005M and nivolumab by testing increasing doses up to 0.3 mg/kg APX005M + nivolumab.
- Phase 2 Evaluate the Objective Response Rate (ORR) by RECIST 1.1 and iRECIST in Each Cohort / Group [ Time Frame: From start of the treatment (Day 1) until disease progression, withdrawal of consent, death, initiation of any anticancer therapy, lost to follow-up, or termination by the Sponsor, whichever comes first (for Phase 2: maximum up to 27 months) ]ORR defined as the rate of patients who show as best overall response; either a complete response (CR) or a partial response (PR). The ORR can be evaluated by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1. using computed tomography (CT) scans/magnetic resonance imaging (MRI). Per RECIST v1.1, for target lesions and assessed by imaging: Complete Response, (CR), Disappearance of all target lesions and nontarget (NT) lesions; Partial Response (PR), >30% decrease in the sum of the longest diameter of target lesions and no PD in NT lesions or new lesions; Objective Response Rate (ORR)=CR + PR.
Secondary Outcome Measures :
- Safety of the APX005M and Nivolumab Combination (Phase 2) [ Time Frame: Day 1 up to 30 days (or 100 days for SAEs and AEs with potential immunologic etiology) following the after the last dose of APX005M and/or nivolumab (from start of treatment up to 27 months) ]Number of participants with TEAEs are reported.
- Duration of Response (DOR) as Per RECIST 1.1(Phase 2) [ Time Frame: Maximum up to 25 months ]Duration of Response is defined as the time from the first evidence of confirmed partial response (PR) or better by Per RECIST v1.1 to disease progression or death due to any cause; in subjects alive without progressive disease (PD), DOR was censored on the date of the last tumor assessment. PD is defined using RECIST v1.1, as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
- Median Progression-free Survival (PFS) (Phase 2) [ Time Frame: From start of treatment (Day 1) up to 27 months ]Progression-free Survival (PFS) in each cohort, measured from first dose to the earlier of PD (by RECIST 1.1) or death due to any cause, whichever occurs first.
- 6-month PFS Rate (Phase 2) [ Time Frame: * Outcome Measure Time Frame From start of treatment (Day 1) to 6 months ]PFS rate in each cohort, measured from first dose to the earlier of PD (by RECIST 1.1) or death due to any cause, whichever occurs first.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Histologically or cytologically confirmed, immunotherapy naïve or PD-1/PD-L1 pre-treated, metastatic or locally advanced non-small cell lung cancer not amenable to curative treatment. Subjects may be treatment naive or could have received one prior platinum based chemotherapy for non-small cell lung cancer and subjects with a documented activating mutation (e.g., EGFR, ALK, ROS) must also have received the appropriate therapy and progressed
- Histologically or cytologically confirmed unresectable or metastatic melanoma that progressed during treatment with an anti-PD-1/PD-L1 therapy and had confirmation of PD>=4 weeks later. Subjects with BRAF activating mutation could have also received a BRAF inhibitor and/or MEK inhibitor regimen prior to anti-PD-1/PD-L1 therapy.
- Measurable disease by RECIST 1.1
- ECOG performance status of 0 or 1
- Adequate bone marrow, liver and kidney function
- Negative pregnancy test for women of child bearing potential
- Agreement to use effective methods of contraception per the protocol requirements
Exclusion Criteria:
- Previous exposure to any immunomodulatory agents (e.g., anti- CD40, anti-PD-1/PD-L1, anti-CTLA-4, IDO inhibitors) except PD-1/PD-L1 targeting agents in the subsets of patients that must have previous treatment with anti-PD-1/PD-L1 therapy
- Second malignancy (solid or hematologic) within the past 3 years except locally curable cancers that have been apparently cured
- Active, known, clinically serious infections within the 14 days prior to first dose of investigational product
- Use of systemic corticosteroids or other systemic immunosuppressive drugs
- Active, known or suspected autoimmune disease
- History of (non-infectious) pneumonitis that required corticosteroids or current pneumonitis
- History of interstitial lung disease
- History of life-threatening toxicity related to prior anti-PD-1/PD-L1 treatment for subjects with metastatic melanoma or NSCLC.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03123783
Locations
Show 23 study locations
Sponsors and Collaborators
Apexigen America, Inc.
Bristol-Myers Squibb
Investigators
| Study Director: | Medical Director | Pyxis Oncology, Inc |
Study Documents (Full-Text)
Documents provided by Apexigen America, Inc.:
Documents provided by Apexigen America, Inc.:
Study Protocol [PDF] October 10, 2019
Statistical Analysis Plan [PDF] February 4, 2021
| Responsible Party: | Apexigen America, Inc. |
| ClinicalTrials.gov Identifier: | NCT03123783 |
| Other Study ID Numbers: |
APX005M-002 |
| First Posted: | April 21, 2017 Key Record Dates |
| Results First Posted: | December 5, 2023 |
| Last Update Posted: | December 26, 2023 |
| Last Verified: | December 2023 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by Apexigen America, Inc.:
|
CD40 Immunotherapy Nivolumab APX005M PD-1 |
Additional relevant MeSH terms:
|
Lung Neoplasms Carcinoma, Non-Small-Cell Lung Melanoma Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases Carcinoma, Bronchogenic Bronchial Neoplasms Neuroendocrine Tumors |
Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms, Nerve Tissue Nevi and Melanomas Skin Neoplasms Skin Diseases Nivolumab Antineoplastic Agents, Immunological Antineoplastic Agents Immune Checkpoint Inhibitors Molecular Mechanisms of Pharmacological Action |